Lonza outlines strategy, new organizational structure and guidance

The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities

Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial

First and only PARP inhibitor to improve overall survival in early breast cancer

LVMH Recherche and Integrated Biosciences partner to discover anti-aging chemical entities

Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging

Laurus Labs invests in Laurus Bio

Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market

Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr

Aims to become India’s leading cancer testing company

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination

For people with relapsed or refractory diffuse large B-cell lymphoma

Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands

The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market

Aster and Blackstone-backed Quality Care to merge and create hospital chains in India

Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals